Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress

Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress
Wedbush initiated coverage on Zenas BioPharma, a clinical-stage biopharmaceutical company focusing on autoimmune disease therapies. ZBIO started trading on NASDAQ after raising $258.7 million in an IPO.